Lisanti Capital Growth’s Intersect ENT, Inc XENT Stock Holding History

Lisanti Capital Growth’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-57,380	Closed	-$2.25M	–	164
2018 Q1	$2.25M	Buy	57,380 +12,170	+27%	+$445K	1.09%	38
2017 Q4	$1.47M	Buy	45,210 +27,165	+151%	+$815K	0.84%	47
2017 Q3	$562K	Sell	18,045 -6,765	-27%	-$200K	0.35%	92
2017 Q2	$693K	Buy	+24,810	New	+$562K	0.46%	92
2015 Q4	–	Sell	-43,054	Closed	-$1.01M	–	111
2015 Q3	$1.01M	Buy	43,054 +4,259	+11%	+$118K	0.91%	53
2015 Q2	$1.11M	Buy	+38,795	New	+$1.02M	0.8%	67

Other funds holding XENT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Lisanti Capital Growth's XENT Position: Q2 2018 in Review

Lisanti Capital Growth sold out of Intersect ENT, Inc (XENT) in Q2 2018, closing a stake of 57,380 shares — an estimated $2.25M sold.

Lisanti Capital Growth first reported a position in XENT in Q2 2015 and held it in 6 quarters. The position peaked at $2.25M in Q1 2018. 160 funds tracked by Wall St. Rank hold XENT as of Q2 2018.

Lisanti Capital Growth reported no remaining Intersect ENT, Inc position as of Q2 2018 after selling out during the quarter.
Lisanti Capital Growth sold 57,380 Intersect ENT, Inc shares in Q2 2018, an estimated $2.25M.
Lisanti Capital Growth first reported a position in Intersect ENT, Inc in Q2 2015 and held it in 6 quarters.
Lisanti Capital Growth's Intersect ENT, Inc position peaked at $2.25M in Q1 2018.
160 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2018.

Based on Lisanti Capital Growth's 13F filing for Q2 2018, filed 13 Aug 2018.